keyword
MENU ▼
Read by QxMD icon Read
search

Pomalyst

keyword
https://www.readbyqxmd.com/read/27668057/pomalyst-pomalidomide-received-a-new-indication-for-patients-with-relapsed-and-or-refractory-multiple-myeloma
#1
Lisa A Raedler
No abstract text is available yet for this article.
March 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27581964/pomalidomide-pomalyst-%C3%A2-capsule-1%C3%A2-mg-2%C3%A2-mg-3%C3%A2-mg-4%C3%A2-mg-pharmacokinetics-pharmacodynamics-and-clinical-study-outcome
#2
Kaoru Torigoe, Naoki Nakayama, Hiroyuki Achiwa
No abstract text is available yet for this article.
September 2016: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/25988965/pomalidomide-pomalyst-for-multiple-myeloma
#3
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
April 27, 2015: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/25004945/impact-of-pomalidomide-therapy-in-multiple-myeloma-a-recent-survey
#4
REVIEW
Arvind Kumar, Mayur Porwal, Ankita Verma, Arun K Mishra
Pomalidomide (Pomalyst(®)) is a synthetic compound derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects and third drug in the class of immunomodulatory drugs. Pomalidomide is under global development with Celgene Corporation, was approved by the U.S. Food and Drug Administration on February 8, 2013 to treat patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including bortezomib and lenalidomide...
December 2014: Journal of Chemotherapy
https://www.readbyqxmd.com/read/24876816/new-drugs-in-multiple-myeloma-role-of-carfilzomib-and-pomalidomide
#5
REVIEW
Artur Jurczyszyn, Wojciech Legieć, Grzegorz Helbig, Marek Hus, Sławomira Kyrcz-Krzemień, Aleksander B Skotnicki
Carfilzomib (CFZ), an epoxyketone with specific chymotrypsin-like activity, is a second-generation proteasome inhibitor with significant activity in patients with relapsed and refractory multiple myeloma. On July 20, 2012, the US Food and Drug Administration approved CFZ to treat patients with multiple myeloma who have received at least two prior therapies including bortezomib (BORT) and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy...
2014: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/24590685/pomalidomide-a-review-of-its-use-in-patients-with-recurrent-multiple-myeloma
#6
REVIEW
Lesley J Scott
Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several countries for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy (or progression within the last 60 days in the USA). The key therapeutic mechanisms of action of pomalidomide, a thalidomide analogue, reside in its immunomodulatory, antiproliferative and anti-angiogenic effects...
April 2014: Drugs
https://www.readbyqxmd.com/read/24086951/pomalidomide-for-patients-with-multiple-myeloma
#7
J Gras
Multiple myeloma is a malignancy of plasma cells in the bone marrow. Currently, multiple myeloma is not considered curable, but it is treatable with different strategies that can combine chemotherapy with autologous hematopoietic stem cell transplantation. Pomalidomide is an orally active thalidomide analogue that has a pleiotropic mechanism of action involving oncolytic, antiangiogenic, immunomodulatory and anti-inflammatory activities. Pomalidomide is extensively metabolized, mainly by the cytochrome P450 3A4 and 1A2 pathways...
September 2013: Drugs of Today
https://www.readbyqxmd.com/read/23572409/pomalidomide-first-global-approval
#8
REVIEW
Shelley Elkinson, Paul L McCormack
Pomalidomide (Pomalyst(®)) is a small molecule analogue of thalidomide under development with Celgene Corporation for the oral treatment of haematological and connective tissue diseases. Pomalidomide has been approved in the USA and is awaiting approval in the EU for use with low-dose dexamethasone for the treatment of relapsed and refractory multiple myeloma that has progressed following at least two prior therapies, including lenalidomide and bortezomib. The efficacy and safety of pomalidomide as monotherapy in patients with relapsed and refractory multiple myeloma has also been evaluated in a phase III trial...
May 2013: Drugs
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"